Riskpilot← Back to searchSign inGet full accessCardiocon Aktiebolag
ABActiveOrg 5565383501Sickla Allé 55Research and experimental development on natural sciences and engineering · NACE 7210Est. 19970 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
88.7%
Financial strength
Net profit 2024
SEK -1K
-108% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK -1K | -108% |
| Total assets | SEK 826K | -1% |
| Equity | SEK 733K | +0% |
| Employees | 0 | — |
Legal name
Cardiocon Aktiebolag
Org number
5565383501
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 januari 1997
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva rådgivande och konsulterande verksamhet inom medicin, läkemedelsutveckling och läkemedelsanvändning, deltaga i utveckling av nya läkemedel och behandlingar inom sjukvården, köpa och sälja värdepapper för att ha en god kapitalförvaltning samt idka därmed förenlig verksamhet.
Address
Sickla Allé 55
Phone
+4684488058
Email
katarina@katarinaarvidson.name
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Net financials | — | — | — | — | 1 |
| Profit before tax | 0 | 0 | 44 | 15 | −1 |
| Tax | −0 | −0 | −10 | −3 | −0 |
| Net profit | 0 | 0 | 34 | 12 | −1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 830 | 827 | 827 | 837 | 826 |
| Equity | 688 | 688 | 722 | 734 | 733 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 64 | 61 | 71 | 84 | 74 |
| Total debt | 64 | 61 | 71 | 84 | 74 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
88.7%
This company
38.2%
Market median
+132% vs market
20202024
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20202024
Net profit margin
-100000.0%
This company
8.1%
Market median
-1234668% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AA Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Cardiocon Förvaltning AB
Cardiocon Aktiebolag Board members of Cardiocon Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna-Britt Andersson | Chief Executive Officer | 0 companies |
| Erik Mikael Andersson | Deputy Board Member | 0 companies |